Earnings
Ascendis Pharma Adds Growth-Hormone Group To Combination Trial — Regulatory Feedback Delays The Study
The larger study must establish each drug's contribution as Ascendis pursues benefits beyond height for children with achondroplasia.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
The larger study must establish each drug's contribution as Ascendis pursues benefits beyond height for children with achondroplasia.
Earnings
Management expects customer advances and contract-backed borrowing to finance 75%–85% of its planned 2027 capital spending.
Earnings
Management's 99% retention figure tracks revenue, not customers, as CAE shrinks its training network.
SEC Filings
AI voice agents handle 65% of inbound servicing calls, and the incoming director runs operations at Datadog.
SEC Filings
The independent directors joined the audit and executive compensation committees, with shareholder elections scheduled for 2027.
SEC Filings
Kaynes Technology would retain 51%, while Vishay would choose equipment and vendors and approve outside customers.
Earnings
December's interim results will assess early activity, while management plans to use the full 26-week results to choose late-stage doses.
SEC Filings
Chris Koegel's appointment needs regulatory approval, with Niclas Neglén staying as finance chief through the end of 2026.
SEC Filings
Colette Kress will keep her CFO duties as the board considers internal and external candidates for a permanent successor.
Earnings
A planned royalty buyback should bring approximately $525 million in early December, while the board weighs dividends against deal opportunities.
SEC Filings
The company expects about $27.7 million after expenses, with lender relief tied to a prepayment of at least $15 million.
Earnings
Domestic programs represent about 25% of drone backlog, while management expects revenue growth at the lower end of its outlook.